Elevance Health (ELV) is back in focus after its Q1 2026 earnings topped revenue and adjusted EPS expectations. The company also lifted full year EPS guidance and highlighted firm medical cost control.

The Q1 beat and higher guidance arrive after a sharp 19.6% 1 month share price return and a 10% 3 month share price return. However, the 1 year total shareholder return of a 7.6% decline and 3 year total shareholder return of a 14.3% decline indicate that long term performance has been weaker and that recent momentum is rebuilding from a lower base.

If earnings driven moves like Elevance Health's have your attention, this could be a moment to broaden your search and check out 35 healthcare AI stocks

With Q1 beating expectations, guidance higher, and the stock still showing a 7.6% 1-year total shareholder return decline, is Elevance Health now trading below its intrinsic value, or has the recent rebound already priced in future growth?

Most Popular Narrative: 4.5% Undervalued

The most followed narrative puts Elevance Health's fair value at $390.54 versus a last close of $372.92. This frames Q1's beat inside a modest undervaluation call built on long term cash flow assumptions.

As a potential growth investment, Elevance Health offers a mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience. Strategic timing and close monitoring of market and operational trends will be important for investors who are evaluating its growth potential over the next 1-3 years.

Curious what sits behind that fair value number? The narrative leans on specific assumptions for earnings growth, margins, and the future profit multiple. The mix might surprise you.

Result: Fair Value of $390.54 (UNDERVALUED)

However, that story can crack if Medicaid pressures persist or medical costs stay elevated, which would squeeze margins and challenge the cash flow assumptions behind the 4.5% undervaluation.

Next Steps

With sentiment clearly mixed, this is a good time to look at the numbers yourself and decide how you see the risk reward trade off. To round out your view, take a closer look at the 4 key rewards

Looking for more investment ideas?

If Elevance Health is on your radar, do not stop there. Broaden your watchlist with curated stock ideas that match different goals and risk levels.

• Target potential bargains by scanning companies flagged as 51 high quality undervalued stocks and see which ones fit your return expectations and risk tolerance.
• Prioritize resilience and sleep easier at night by checking out 71 resilient stocks with low risk scores that focus on steadier profiles and lower risk scores.
• Get ahead of the crowd by reviewing the screener containing 23 high quality undiscovered gems and see which quieter opportunities might deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.